Letrozole and norethisterone acetate versus letrozole and triptorelin in the treatment of endometriosis related pain symptoms: a randomized controlled trial

Table 1 Intensity of pain symptoms at baseline and during treatment

	VAS scale			Multidimensional categorical rating scale
	group T (n = 18)	group N (n = 17)	p	group T (n = 18)	group N (n = 17)	p
Dysmenorrhea
- baseline	8.7 ± 1.1 (n = 18)	8.6 ± 1.3 (n = 16)	0.881	3 (2-3) (n = 18)	3 (0-3) (n = 17)	0.890
Nonmenstrual pelvic pain
- baseline	6.1 ± 1.4 (n = 16)	6.0 ± 1.4 (n = 14)	0.783	2 (0-3) (n = 18)	2 (0-3) (n = 17)	0.957
- 3 months of treatment	3.2 ± 1.3 (n = 15)	3.3 ± 1.5 (n = 14)	0.782	1 (0-2) (n = 17)	1 (0-2) (n = 17)	0.818
- 6 months of treatment	1.2 ± 1.3 (n = 9)	2.0 ± 1.8 (n = 14)	0.286	0 (0-2) (n = 10)	1 (0-2) (n = 16)	0.171
p value: 3 month of treatment vs baseline	< 0.001	< 0.001		< 0.001	< 0.001
p value: 6 month of treatment vs baseline	< 0.001	< 0.001		0.004	< 0.001
p value: 6 month of treatment vs 3 month	0.001	< 0.001		0.063	0.156
Deep dyspareunia ^a
- baseline	6.4 ± 1.9 (n = 12)	6.6 ± 2.1 (n = 14)	0.801	2 (0-3) (n = 14)	2 (0-3) (n = 15)	0.501
- 3 months of treatment	3.4 ± 1.2 (n = 11)	3.6 ± 1.5 (n = 14)	0.635	1 (0-2) (n = 13)	1 (0-2) (n = 15)	0.853
- 6 months of treatment	2.0 ± 0.9 (n = 4)	2.2 ± 1.4 (n = 13)	0.727	1 (0-1) (n = 6)	1 (0-2) (n = 14)	0.406
p value: 3 month of treatment vs baseline	< 0.001	< 0.001		0.031	< 0.001
p value: 6 month of treatment vs baseline	0.022	< 0.001		0.042	< 0.001
p value: 6 month of treatment vs 3 month of treatment	0.088	< 0.001		0.076	0.125

^a14 women included in group T and 15 women included in group N were sexually active at the time of the study
The intensity of each pain symptom was measured only for patients suffering the symptom; the multidimensional categorical rating scale was calculated for all the patients because this scale includes the 0 for patients not suffering the symptom

ISSN: 1477-7827